LEXXW vs ROL · rev $705.9K vs P/E 41, rev $1.99B
Lexaria Bioscience Corp (LEXXW) versus Rollins Inc (ROL) — a side-by-side from cached financials, not a winner call.
Lexaria Bioscience Corp (LEXXW) common stock listed on US.
Rollins Inc (ROL) is a personal services company listed on NYSE.
Latest reported LEXXW revenue for 2025-08-31 was $705.9K. Net income was -$11.9M. Revenue was up 52.0% from 2024-08-31 to 2025-08-31. LEXXW currently screens at market cap $33.8M.
Latest reported ROL revenue for 2026-06-30 was $1.99B. Net income was $251.7M. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
LEXXW currently screens at market cap $33.8M. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
Not investment advice. Open the LEXXW and ROL stock pages for the full models.
Not investment advice.